Comparing two seizure drugs in people with glioma
Original title: Seizure Treatment in Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a late-stage trial comparing two drugs that doctors already use.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial compares two seizure medicines in people with a brain tumor called glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
Who this trial is for. This trial is for people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary who have had a first seizure. It compares two anti-seizure drugs, levetiracetam and valproic acid, to see how well each one works.
Where it stands. The trial has not reported results. It is measuring how well each drug works at treating seizures in these patients. Right now, doctors pick one drug or the other based on their own preference. No study has shown which one is better. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Doctors do not yet know which of these two seizure drugs works better for glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. This trial is trying to answer that. Someone with glioma who has had a seizure could ask their care team about it.
What it doesn't mean: This does not mean either drug has been shown to be the better choice. A trial is a test, not proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.